Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: A small Swiss study released on Monday showed that walking up and down stairs for three months, without recourse to the lift, increased levels of fitness dramatically. In fact, the improvement in aerobic capacity was equivalent to a 15 percent fall in the risk of dying prematurely from any cause. Subjects also saw marked reduction in waist size, body fat, blood pressure and cholesterol — all of which are known risk factors for heart disease. Philippe Meyer of the University Hospital in Geneva studied 69 employees of the university with a sedentary lifestyle, defined as less than two hours of exercise a week and fewer than 10 flights of stairs climbed a day. After not using elevators for 12 weeks, they increased their use of stairs to an average of 23 stories ascended or descended a day from five before, with a resulting sharp increase in fitness levels. “This suggests that stair climbing at work may have major public health implications,” Meyer told the annual meeting of the European Society of Cardiology. “However, the results of the pilot study need to be confirmed in a larger randomized controlled trial.” Claim: Take the stairs for a healthy heart.

Output: Using the stairs at work instead of taking elevators could be a life saver.


Input: Consider Input: Paragraph: A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville The GlaxoSmithKline Plc vaccine Rotarix fights infection with the rotavirus, which causes about 55,000 hospitalizations in U.S. children each year and kills more than 600,000 children worldwide, mostly in developing countries. Rotarix already is approved in more than 100 other countries throughout the world. The vaccine competes with Merck & Co Inc’s rotavirus vaccine called RotaTeq. Without vaccination, nearly every child in the United States likely would be infected at least once with rotavirus by age five, the Food and Drug Administration said. In studies of more than 24,000 infants, Rotarix prevented severe and mild cases of rotavirus-caused diarrhea and vomiting during the first two years of life. “This vaccine provides another option to combat and reduce a potentially severe illness that affects so many children,” Dr. Jesse Goodman, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement announcing the Rotarix approval. The most common reactions reported during clinical trials were fussiness, irritability, cough, runny nose, fever, loss of appetite and vomiting, the FDA said. An earlier oral rotavirus vaccine sold by Wyeth was pulled from the market in 1999 after it was linked to a rare, life-threatening type of bowel obstruction known as intussusception. In a Glaxo study of more than 63,000 infants, there was no increase in the problem compared with a placebo. Higher rates of convulsion and pneumonia-related deaths were seen in Rotarix patients in that study but not in other Glaxo trials. “Although the FDA has concluded that the available data do not establish that these events are related to the vaccine, the agency has requested the manufacturer to conduct post-marketing safety studies involving more than 40,000 infants to provide additional safety information,” the FDA said. Glaxo said Rotarix “will offer protection against the most commonly circulating rotavirus types in the U.S. and allow infants to complete the vaccination series by four months of age.”   Rotarix, which is a liquid, is given in two doses to infants from six to 24 weeks of age, the FDA said. Merck’s RotaTeq vaccine is administered in three doses from ages six weeks to 32 weeks. Sales of Rotarix were $182 million in 2007 and are expected to rise with approval in the large U.S. market. The vaccine will be commercially available in the United States in the second half of the year, Glaxo said. Also on Thursday, researchers reported that Rotarix provided protection for up to two years in a study of infants from 10 Latin American countries. The Glaxo-funded trial of more than 15,000 infants found severe diarrhea from rotavirus in 0.4 percent of children given the vaccine, compared with 2.3 percent in the placebo group. Results were published in the Lancet medical journal. The arrival of a new generation of oral vaccines against the disease has been welcomed by health-care workers, but some experts caution against assuming the vaccines will work equally well in all countries. In a commentary in the Lancet, Australian pediatric experts Keith Grimwood and Carl Kirkwood noted Rotarix was more effective in European trials than in middle-income Latin American countries. The World Health Organization “is awaiting efficacy data from low-income countries of Africa and Asia, where much greater strain diversity exists and where 413,000 deaths occur every year compared with 15,000 in Latin America and 200 in Europe,” Grimwood and Kirkwood wrote. Claim: Glaxo wins FDA clearance for rotavirus vaccine.

Output: A second oral vaccine to prevent a leading cause of severe diarrhea in infants won approval from U.S. health officials on Thursday.


Input: Consider Input: Paragraph: WMUR-TV reports the New Hampshire Bureau of Infections Disease Control has raised the risk level in Fremont high, where a batch positive for Eastern equine encephalitis in September. Batches for the virus also have tested positive for the disease in Pelham, Manchester, Candia, Sandown, Hampstead and Newton. There have been no human cases of the virus. It was found in a horse in Northwood in August. Claim: Eastern equine encephalitis detected in 2 more communities.


Output: New Hampshire health officials say that Eastern equine encephalitis has been detected in three mosquito batches, one in Portsmouth and two in Fremont.